anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Influenza virus is known for its severe course of infection and systemic effects, associated with high mortality rates. Recent work has shown that influenza promotes susceptibility for secondary bacterial infections, thereby worsening the prognosis. While it has become clear that bacterial infections induce an immunosuppressed state in which the immune response against viral infections is attenuated1, it is unknown how a bacterial infection, such as in sepsis, influences the susceptibility and immune response to influenza. The sepsis-induced immunosuppressive state, called "immunoparalysis", may be a major contributor to this increased vulnerability. Because of the high mortality rates of both sepsis and influenza, it is of main importance to understand this interaction for the development of putative preventive and therapeutic interventions in ICU patients.

Human endotoxemia represents a model of systemic inflammation, mimicking bacterial sepsis and subsequent development of immunoparalysis. The live, attenuated, quadrivalent influenza vaccine "Fluenz™" is registered in the European Union and can be used as a surrogate for an actual influenza infection. In this study, we want to investigate the effects of an endotoxemia challenge on the Fluenz™-induced inflammatory response to present unique in vivo data on mechanistic interactions of systemic LPS followed by mucosal Fluenz™, thereby providing clues regarding the increased vulnerability towards viral infections in septic patients and open up new avenues to investigate therapeutic measures to prevent this. Furthermore, it provides important implications regarding the safety and efficacy of the vaccine in (post)septic or immunocompromised patients.

Objective: Our primary objective is to investigate the effects of endotoxin-induced systemic inflammation and subsequent development of endotoxin tolerance on the inflammatory response following Fluenz administration in vivo. To evaluate whether these effects involve local and/or systemic inflammation, symptoms, temperature and peak expiratory flow will be measured. Next, local inflammatory parameters are measured in nasal wash and systemic inflammatory parameters are measured in blood. Furthermore, we want to evaluate whether preceding endotoxemia influences the viral shedding of influenza in nasal wash. Also, changes in the mucosal microbiome, transcriptome and metabolome will be assessed. Finally, mitochondrial function and mental strength during human endotoxemia will be assessed.
ETHNOPHARMACOLOGICAL RELEVANCE: Moluodan concentrated pill (MLD) is a traditional herbal formula used in China for the treatment of chronic atrophic gastritis (CAG). However, its pharmacological mechanism of action remains unclear.
AIM OF THE STUDY: The aim of this study was to investigate the therapeutic effect and mechanism of action of MLD in the treatment of CAG using network pharmacology and in vivo experiments.
MATERIALS AND METHODS: The active compounds of MLD were determined using network pharmacology, utilizing various Chinese medicine databases such as the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Traditional Chinese Medicine Integrated Database, Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine, and a comprehensive database of Traditional Chinese Medicine on Immuno-Oncology. The compounds found in the root of Anemone altaica Fisch. were extracted from the China National Knowledge Infrastructure literature database. Additionally, the Swiss Target Prediction database and Similarity Ensemble Approach were employed to identify the potential targets of these components. CAG-related targets were gathered from the GeneCards and DisGeNET databases. Protein-protein interactions (PPIs) of the genes associated with the drug-disease crossover were examined, and a core PPI network was constructed using the STRING database (version 11.5) and Cytoscape (version 3.7.2). A gene-pathway network was established to identify significant target genes and pathways through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Finally, based on these findings and existing data, the tumor necrosis factor (TNF) signaling pathway was selected for further validation through in vivo experiments.
RESULTS: A total of 724 active molecules in MLD yielded 961 identified target genes, of which 179 were found to be potentially associated with CAG. From the common targets, a PPI network revealed ten core targets. Enrichment analysis suggested that MLD may primarily target TNF and AKT in the treatment of CAG. Essential signaling pathways, such as the PI3K-AKT and TNF pathways, were found to be crucial for the therapeutic effects of MLD on CAG. Furthermore, potential interactions and crosstalk between these pathways were identified. Moreover, we confirmed that MLD effectively improved gastric mucosa atrophy and cellular ultrastructural damage, while increasing pepsinogen secretion and decreasing gastrin, somatostatin, and motilin levels. Subsequent molecular biology studies in rat models of CAG demonstrated that MLD treatment significantly reduced the expression levels of TNF-α, phosphatidylinositol 3'-kinase (PI3K), and phosphorylated Akt (P < 0.05). Notably, the expression of nuclear factor kappa-B (NF-κB) exhibited a contrasting trend (P < 0.05), potentially associated with the crucial tumor suppressor role of NF-κB p105.
CONCLUSION: This study provides evidence that MLD effectively alleviates stomach mucosal atrophy through modulation of the TNF/PI3K/AKT signaling pathway. These findings establish a solid theoretical foundation for the practical management of CAG.
NEW MATERIAL:The compound of formula I (R<1> is H or OH; R<2> is amino or OH; R<3> is H or trifluoroacetyl). EXAMPLE:4-Demethoxy-13-hydroxydaunomycin. USE:A carcinostatic agent having low side effect and high safety. PREPARATION:The compound of formula I can be produced either by reacting the compound of formula II (R is H or acyloxy) (e.g. 4-demethoxy-N-trifluoroacetamidodaunomycin) with a reducing agent (e.g. sodium cyanoborohydride) usually in a solvent such as alcohol, etc., or by reacting the compound with a reducing agent in the presence of an ammonium salt, and if necessary hydrolyzing the resultant compound of formula III.
Type II Diabetes is a prevalent chronic disease with poor outcomes, and requires daily self-care, including blood glucose monitoring, following a diabetes-friendly diet, engaging in regular physical activity, and medication adherence. Patients with diabetes benefit from comprehensive diabetes self-management education (DSME) and self-management support (SMS) in primary care. Shared medical appointments (SMAs) are one way to efficiently and effectively provide DSME and SMS. SMAs can have a variety of different features, but it is not known which features are most effective for which types of patients. Patients and other stakeholders engaged in planning this study proposed a model with "diabetes' veterans" (i.e., diabetes peer mentors) who co-facilitating group visits with a variety of diabetes care professionals, and then working one-on-one with patients to help apply what they learned. The group visit curriculum should include topics on physical activity, healthy eating, taking medication, acceptance and coping, and social support, and each cohort of patients should get to select topics most relevant to them. The practice stakeholders want to do more comprehensive group visit models, but need to know the extent to which SMA participation and patient-centered outcomes are improved compared to the more common standardized approaches they tend to use now.

In this study, the investigators will compare the effectiveness of patient-driven diabetes SMAs to standardized diabetes SMAs. The curriculum to be used is Targeted Training for Illness Management (TTIM), a 6-session modular group intervention for chronic illness self-management, and has been tested in diabetes. The standardized group visit model will consist of diabetes SMAs with the full TTIM 6-session curriculum, led by a health educator. For the patient-driven SMAs, patients choose the topics and the order of sessions from the TTIM curriculum, which is delivered collaboratively by the multidisciplinary care team consisting of several professional providers (health educator, medical provider, and behavioral health provider) and a lay worker (diabetes peer mentor). The primary patient-centered outcome, selected by patient stakeholders, is diabetes distress. Secondary outcomes include autonomy support and diabetes self-management behaviors, clinical outcomes (hemoglobin A1c, blood pressure, and body mass index), patient reach and engagement, and practice-level value and sustainability. Patient, caregiver, practice, health plans, and research stakeholders will be engaged in all aspects of the research. Patients and other stakeholders will inform the process of implementation of patient-driven and standardized SMAs, help finalize the research protocol (including data collection and recruitment), and contribute to interpretation of findings and dissemination of findings, including messages that help other patients make decisions about whether or not to participate in SMAs.
One way that cumulus cells influence oocyte competence is via metabolism (Dumesic et al., 2015). Analysis of mitochondria respiration is an established methodology used for evaluation of cell metabolic homeostasis and for diagnosis of different pathologies.
An Internet-based drag and drop signature and date placement system is used by users such as lawyers, doctors, patients, nurses, home health care agencies, hospitals, etc. to gets documents signed after creators of the documents specify the signature and date locations and save them with or in the documents that need to be signed. The servers that store and provide documents employ digital certificates and other security mechanisms to make the retrieval of documents secure. Users therefore need digital certificates to retrieve documents from a secure document server before being able to sign them. A signer needs to have his signature captured once as ad electronic image signature so as to be able to use them for signing purposes subsequently. The creator of a document employs a document viewer on his computer or browser to drag and drop signature and/or date locations on his documents. The signature and date locations thus specified are saved, over the Internet, along with the document, and are subsequently used for placing electronic image signatures of signers when they sign the document, and for inserting dates as appropriate. More than one signers may be required to sign a document, and the order in which they must sign can be specified.
FIELD: biotechnology. SUBSTANCE: invention relates to the use of amino acid and dipeptide derivatives of fullerene as immune response stimulating agents - adjuvants and can be used in biological industry for development and production of vaccines. Invention relates to the use of the early described fullerene derivatives of amino acid and dipeptides of the general formula (I) as adjuvants: C 60 -X where C 60  is fullerene ring; X is NH-CHR-COOH, NH-(CH 2 ) h -COOH, NH-CHR-CO-NH- -CHR-COOH where n = from 2 to 6; R - side radical of natural amino acid. In experiments with human erythrocytes an invention provides a capability to use high doses (400 mcM) but even they do not exhibit hemolytic properties. During incubation cells are not agglutinated and their morphology is constant. Administration of these compounds to mice at high dose 80 mg/kg does not change their viability and behavior for 6 months. EFFECT: improved quality and properties of adjuvants. 2 tbl, 9 ex
The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.
<P>PROBLEM TO BE SOLVED: To obtain a composition for breast enlargement, which provides developed and beautiful busts and has excellent breast enlargement effect of increasing a cup size.  <P>SOLUTION: The composition for breast enlargement comprises a collagen as an active ingredient. The collagen is preferably a collagen peptide having an average molecular weight of ≤10,000 and is preferably derived from fish. The collagen has a free amino acid content of ≤1.0 mass% and an arsenic content of ≤2 ppm. The dosage form is preferably tablet, capsule, powder, granule or liquid. The composition for breast enlargement is mixed with a food and beverage, an external preparation, etc., and taken or applied so that the collagen being the active ingredient is quickly absorbed, used for a raw material for busts to develop busts and to obtain an excellent breast enlargement effect of increasing a cup size.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention relates to a medicine and particularly relates to an externally applied or orally taken medicine for treating haemorrhoids and a preparation method thereof. The externally applied medicine for treating haemorrhoids comprises 100 parts of lumbricus and 50 parts of sorghum rice with bran. The preparation method of the externally applied medicine for treating haemorrhoids comprises the following steps: crushing sorghum rice with bran; adding the sorghum rice with bran and lumbricus together into 2000-3000 parts of water; and boiling for 5-6 minutes. The orally taken medicine for treating haemorrhoids comprises 50 parts of lumbricus and 50 parts of sorghum rice with bran. The preparation method of the orally taken medicine for treating haemorrhoids comprises the following steps: grinding lumbricus and sorghum rice with bran into powder; adding a proper amount of water to prepare a paste or prepare a biscuit; and putting on a boiling drawer to be steamed. Compared with the prior art, the medicine provided by the invention has the beneficial effects that the medicine is simple in dosing, common and safety, free from any toxic and side effects and simple in preparation and using methods and has the functions of clearing away heat and toxic materials, relieving pains and itching, stopping bleeding and dispersing blood stasis; the method is quick in effect: the medicine is effective within commonly 2-3 days, the patient is substantially cured within 5 days; the cure rate is high: in the past 5 years, about 500 cases of haemorrhoids are treated with the cure rate reaching up to 100%.
Long-term outcomes of persistent pulmonary hypertension of newborn (PPHN) depend on disease severity, duration of ventilation, and associated anomalies. Congenital diaphragmatic hernia survivors may have respiratory morbidities and developmental delay. The presence of PPHN is associated with increased mortality in hypoxic-ischemic encephalopathy, though the effects on neurodevelopment are less clear. Preterm infants can develop pulmonary hypertension (PH) early in the postnatal course or later in the setting of bronchopulmonary dysplasia (BPD). BPD-PH is associated with higher mortality, particularly within the first year. Evidence suggests that both early and late PH in preterm infants are associated with neurodevelopmental impairment.
A total of 250\~300 male and female subjects from the Department of Psychiatry at National Cheng Kung University Hospital. Eligible subjects who are aged between 18\~65 years old and clinically suspected of having bipolar II disorder are invited. The add-on double-blind study treatment with dextromethorphan/place will commence at randomization for while patients continue open-label valproate. Subjects will be enrolled for 12 weeks double-blind add-on treatment and randomly assigned to (1) 30mg dextromethorphan+valproate, (2) 5mg memantine+valproate, (3) dextromethorphan+memantine+valproate or (4) placebo+valproate. Concomitant benzodiazepine medication (preferably up to 8mg lorazepam) may be used for daytime sedation, agitation or insomnia during the study. For the consideration of the less influence to immune-system, resperidone 1-3mg/daily and fluoxetine maximum 20mg/daily will be chose. We will measure the treatment response and side effect to clarify the curative effect of DM and memantine add-on therapy to valproate in the treatment of bipolar disorders. This study is being performed to investigate the possibly significant beneficial effects on the subtypes of bipolar disorders psychopathology.
Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH \< 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
PROBLEM TO BE SOLVED: To obtain a medicine inducing the axial growth of the eyes of mature animals and useful for the therapy of the eyes for controlling the development of the eyes, especially for controlling the development of myopia, by adding a choline-operating agonist. SOLUTION: A medicine for inducing the axial growth of the eyes of mature animals contains a therapeutically effective amount of a choline-operating agonist. The choline-operating agonist is preferably carbamylcholine chloride, pilocarpine or M1 muscarine agonist McNeil-A-343. Pirenzepine, a muscarine antagonist having anti-choline eperability, is effective for blocking an axially growing myopia caused by the image blockage of the eyes of a chick. Telenzepine has an effect for blocking the axially growing myopia of mature animals. Other muscarine antagonists capable of being used as factors for blocking the axially growing myopia includes o-methoxy-sila-hexocyclium.
Interventions done in 30 patients and included conventional endodontic treatment (ET) and periodontal surgery . After 3 months of completion of endodontic therapy without using 2%chlorhexidine gluconate gel intracanal medicament , periodontal surgery in the form of open flap debridement (OFD) was performed.
Pharmaceutical composition in solid form containing isoflavones, a calcium salt and vitamin d3. The present invention relates to a new pharmaceutical composition in solid form comprising specific amounts of isoflavones, calcium ions in salt form and vitamin d3. It also relates to the use of said composition to prepare powders for oral suspension, granules for oral suspension, effervescent tablets and dispersible tablets. It also refers to powders for oral suspension, granules for oral suspension, effervescent tablets and dispersible tablets which are prepared with said composition. The composition of the invention is used for the prevention and/or treatment of osteoporosis in women who are in the early stages of menopause and who may suffer mild or moderate symptoms associated with menopause due to the reduction of estrogen. (Machine-translation by Google Translate, not legally binding)
This is an open-label (all people know the identity of the intervention), multi-center (when more than one hospital or medical school team work on a medical research study) early access program (EAP) study. The study will be conducted in 2 phases: a Screening Phase (approximately 30 days prior to administration of first dose) and a Program Drug Phase (Day 1 up to 30 Days after last dose of study drug). Enrolled participants will receive 420 milligram (mg) oral ibrutinib once daily on a 28-day cycle until disease progression, occurrence of unacceptable toxicity, no longer achieving clinical benefit, or the end of program. Treatment will be continuous (without interruption) and self-administered. Disease evaluations will be conducted according to local standard of care as clinically indicated. Participant's safety will be monitored throughout the study. All enrolled and on-going participants in the program will continue to receive ibrutinib by the EAP until marketing approval or 6 months after this date.
Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.
Of the total number of patients in Phase 2/3 double-blind, multiple-dose clinical studies of NUCYNTA ER, 28% (1023/3613) were 65 years and over, while 7% (245/3613) were 75 years and over. No overall differences in effectiveness or tolerability were observed between these patients and younger patients.

Elderly patients (aged 65 or older) may have increased sensitivity to tapentadol. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy [see Clinical Pharmacology (12.3)].

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of NUCYNTA ER slowly in geriatric patients and monitor closely for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.6)].

Tapentadol is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
The most commonly used illicit stimulant in HIV-infected individuals is methamphetamine (MA), and prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation. HIV cure has emerged as an important clinical and research priority given evidence of ongoing immune dysfunction in HIV-infected individuals despite effective antiretroviral therapy (ART). A challenge in achieving worldwide HIV eradication is targeting specific vulnerable populations who are most likely to benefit from an HIV cure but possess poorer immune responses as a result of residual viral replication due to suboptimal ART adherence and/or direct immune dysfunction from illicit substance use. Prior non-human studies demonstrate that MA directly induces HIV production and promotes immune activation and inflammation. These preclinical findings suggest that HIV+ individuals who use MA may experience greater immune dysfunction and face additional challenges for future HIV eradication. This study will investigate the effects of short-term MA exposure in HIV+ ART-suppressed individuals without a prior history of MA use. Participants will be enrolled in an interventional study where they will be administered oral methamphetamine (the maximum FDA approved daily dose for the treatment of childhood obesity) to determine the effects of short-term MA exposure on residual virus production, gene expression, inflammation, and trace amine-associated 1 (TAAR1, a promising drug target for psychostimulant addiction) signaling. MA exposure will be quantified with multiple serum samples collected over a 24-hour monitoring period and associated with residual viral transcription, host gene and cell surface protein expression, and inflammation (plasma inflammatory cytokine levels) quantification. The proposed study will be the first human genetic study to directly evaluate the effect of MA exposure on residual viral transcription during effective ART. The overall goals of the study are to integrate a rigorous clinical study designs with high throughput 'omics data to identify novel targets for reversing HIV latency, reducing inflammation, and personalizing future therapeutic strategies specific to HIV+ ART-suppressed individuals who use MA.